IS5537A - Meðferðarvirk blanda til að gefa tolteródín með stýrðri losun - Google Patents

Meðferðarvirk blanda til að gefa tolteródín með stýrðri losun

Info

Publication number
IS5537A
IS5537A IS5537A IS5537A IS5537A IS 5537 A IS5537 A IS 5537A IS 5537 A IS5537 A IS 5537A IS 5537 A IS5537 A IS 5537A IS 5537 A IS5537 A IS 5537A
Authority
IS
Iceland
Prior art keywords
tolterodine
administer
controlled release
therapeutic formulation
therapeutic
Prior art date
Application number
IS5537A
Other languages
English (en)
Other versions
IS2976B (is
Inventor
Nilvebrant Lisbeth
Hallen Bengt
Olsson Birgitta
Strömbom Jan
Kreilgård Bo
Orup Jacobsen Lene
Hoeck Ulla
Kristensen Helle
Gren Torkel
Ringberg Anders
Wikberg Martin
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of IS5537A publication Critical patent/IS5537A/is
Publication of IS2976B publication Critical patent/IS2976B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IS5537A 1998-08-27 2000-06-15 Lyfjablanda til inntöku um munn sem inniheldur tolteródín og hefur stýrða losun IS2976B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (2)

Publication Number Publication Date
IS5537A true IS5537A (is) 2000-06-15
IS2976B IS2976B (is) 2017-07-15

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5537A IS2976B (is) 1998-08-27 2000-06-15 Lyfjablanda til inntöku um munn sem inniheldur tolteródín og hefur stýrða losun

Country Status (30)

Country Link
US (1) US6770295B1 (is)
EP (2) EP2153825A1 (is)
CN (1) CN1239152C (is)
AP (1) AP1529A (is)
AR (1) AR029311A1 (is)
AT (1) ATE487471T1 (is)
AU (1) AU745190B2 (is)
BG (1) BG65168B1 (is)
CA (1) CA2311755C (is)
CY (1) CY1111088T1 (is)
CZ (1) CZ302630B6 (is)
DE (1) DE69942928D1 (is)
DK (1) DK1039882T3 (is)
EA (1) EA002720B1 (is)
GE (1) GEP20043354B (is)
HU (1) HUP0100437A3 (is)
ID (1) ID25824A (is)
IL (1) IL136294A (is)
IS (1) IS2976B (is)
ME (1) ME00850B (is)
MY (1) MY127946A (is)
NO (1) NO329830B1 (is)
NZ (1) NZ504618A (is)
OA (1) OA11636A (is)
PT (1) PT1039882E (is)
SI (1) SI1039882T1 (is)
SK (1) SK287111B6 (is)
TR (1) TR200001998T1 (is)
UA (1) UA72882C2 (is)
WO (1) WO2000012069A1 (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DK1227806T3 (da) 1999-11-11 2005-10-31 Pfizer Health Ab Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
MXPA04003866A (es) * 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
AU2004206110A1 (en) † 2003-01-22 2004-08-05 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (is) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
RU2301086C2 (ru) * 2004-12-27 2007-06-20 Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ) Способ лечения гиперактивного мочевого пузыря
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
RU2396920C1 (ru) * 2008-12-29 2010-08-20 Николай Владимирович Карюкин Способ лечения гиперактивного мочевого пузыря
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2012017892A1 (ja) * 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
ES2137261T3 (es) * 1992-05-13 1999-12-16 Alza Corp Administracion transdermica de oxibutinina.
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6310103B1 (en) 1996-07-19 2001-10-30 Bridge Pharma, Inc. S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0927034A1 (en) 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
OA11636A (en) 2004-09-03
IL136294A (en) 2004-02-08
GEP20043354B (en) 2004-04-13
SI1039882T1 (sl) 2011-01-31
HUP0100437A3 (en) 2002-08-28
AU5891899A (en) 2000-03-21
SK7492000A3 (en) 2001-02-12
DK1039882T3 (da) 2011-01-24
UA72882C2 (uk) 2005-05-16
NO20002977L (no) 2000-06-09
HK1034664A1 (en) 2001-11-02
CN1287484A (zh) 2001-03-14
ID25824A (id) 2000-11-09
TR200001998T1 (tr) 2001-01-22
AP1529A (en) 2006-01-03
IL136294A0 (en) 2001-05-20
AU745190B2 (en) 2002-03-14
NO20002977D0 (no) 2000-06-09
BG104476A (en) 2000-12-29
CZ302630B6 (cs) 2011-08-10
EA200000468A1 (ru) 2000-12-25
CY1111088T1 (el) 2015-06-11
SK287111B6 (sk) 2009-12-07
AP2000001823A0 (en) 2000-06-30
AR029311A1 (es) 2003-06-25
PT1039882E (pt) 2011-01-03
HUP0100437A2 (hu) 2002-05-29
NO329830B1 (no) 2011-01-03
EP1039882A1 (en) 2000-10-04
BG65168B1 (bg) 2007-05-31
CN1239152C (zh) 2006-02-01
CA2311755C (en) 2010-03-23
US6770295B1 (en) 2004-08-03
WO2000012069A1 (en) 2000-03-09
MY127946A (en) 2007-01-31
CA2311755A1 (en) 2000-03-09
EA002720B1 (ru) 2002-08-29
CZ20001924A3 (cs) 2001-04-11
NZ504618A (en) 2002-09-27
EP1039882B1 (en) 2010-11-10
EP2153825A1 (en) 2010-02-17
ATE487471T1 (de) 2010-11-15
IS2976B (is) 2017-07-15
ME00850B (me) 2008-08-07
DE69942928D1 (de) 2010-12-23

Similar Documents

Publication Publication Date Title
IL136294A0 (en) Therapeutic formulation for administering tolterodine with controlled release
DE69820677D1 (de) Mikrokapseln mit einfach einstellbarer abgaberate
NO941719L (no) Farmasöytisk preparat med regulert frigjöringsvirkning
DE69829254D1 (de) Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
FI950465L (fi) Läpäisevä laastari lääkityksen antamiseksi ihoon
DK1208864T3 (da) Forbedringer til lægemiddelafgivelsesindretninger
ATE209497T1 (de) Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
EE200000595A (et) Toimeaine viimine kandjamaatriksisse
DE69938295D1 (de) Kleinlumiges biologisches transplantat mit therapeutischer verabreichungsvorrichtung
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
DE69925639D1 (de) Glicazidhaltige matrixtablette mit verzögerter wirkstoffverabreichung zur oralen anwendung
ATE257694T1 (de) Expandierbares gastroretentives therapie-system mit verlängerter magenverweildauer
DE69913197D1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
NO20001375D0 (no) Legemiddelformulering med kontrollert virkestoffrigivning
DK0936902T3 (da) Spraytørrede mikropartikler som terapeutiske bærere til anvendelse i terapi
DK1028718T3 (da) Formulering med opretholdt frigivelse indeholdende venlafaxin
IL134075A0 (en) Analgesic with controlled active substance release
FI954497L (fi) Aktiivista ainetta sisältävä laastari estradiolin vapauttamiseksi ihoon
DE60001266D1 (de) Betahistin-hältige formulierung mit kontrollierter wirkstofffreisetzung
ES1041098Y (es) Dispositivo electrovibrador que se coloca en cunas para niños con la finalidad de conciliar el sueño.
NO993435D0 (no) Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
ID17052A (id) Turunan-turunan asam asetat terapeutik
NO971879D0 (no) Preparat for transdermal administrasjon